SGLT2 Inhibitors Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Clinical Trials
• Forums

meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis
Conditions:   Peritoneal Dialysis Complication;   End Stage Kidney Disease;   Sodium-glucose Co-transporter-2 Inhibitors;   Kidney Dysfunction;   Residual Kidney Function Intervention:   Drug: Empagliflozin 25 MG Sponsor:   University Health Network, Toronto Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2023 Category: Research Source Type: clinical trials